Recent ZVSA News
- ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/31/2026 09:05:00 PM
- ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/19/2025 09:20:00 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 10/06/2025 06:18:48 PM
- ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes • GlobeNewswire Inc. • 09/10/2025 11:55:00 AM
- ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression • GlobeNewswire Inc. • 09/03/2025 11:55:00 AM
- ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression • GlobeNewswire Inc. • 08/14/2025 11:55:00 AM
- ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones • GlobeNewswire Inc. • 08/13/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2025 11:55:50 AM
- ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress • GlobeNewswire Inc. • 07/21/2025 11:55:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2025 04:55:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2025 04:40:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2025 08:22:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2025 08:22:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2025 08:15:51 PM
- ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds • GlobeNewswire Inc. • 07/08/2025 04:30:00 PM
- ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis • GlobeNewswire Inc. • 07/08/2025 11:52:00 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/02/2025 01:50:35 AM
- ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD) • GlobeNewswire Inc. • 06/26/2025 11:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/25/2025 01:00:45 PM
- ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200 • GlobeNewswire Inc. • 06/25/2025 11:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2025 08:47:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2025 08:15:40 PM
- ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases • GlobeNewswire Inc. • 05/20/2025 12:52:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2025 08:37:07 PM
- ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress • GlobeNewswire Inc. • 05/12/2025 08:35:00 PM
